BRPI0416980A - formulações lìquidas de interferon estabilizadas - Google Patents
formulações lìquidas de interferon estabilizadasInfo
- Publication number
- BRPI0416980A BRPI0416980A BRPI0416980-8A BRPI0416980A BRPI0416980A BR PI0416980 A BRPI0416980 A BR PI0416980A BR PI0416980 A BRPI0416980 A BR PI0416980A BR PI0416980 A BRPI0416980 A BR PI0416980A
- Authority
- BR
- Brazil
- Prior art keywords
- interferon
- formulations
- cyclodextrin
- room temperature
- stable
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/215—IFN-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
"FORMULAçõES LìQUIDAS DE INTERFERON ESTABILIZADAS". São descritos aqui composição farmacêutica líquida estabilizada compreendendo um interferon (IFN) ou uma isoforma, muteína, proteína fundida, derivado funcional, fração ativa ou sal dos mesmos, em que a referida formulação é uma solução que compreende um tampão, uma ciclodextrina, um agente de isotonicidade e um anti-oxidante. Preferencialmente o interferon é interferon beta-1a e a ciclodextrina é HPBCD. Estas formulações são estáveis em temperatura ambiente, deste modo trazendo a vantagem de menores custos para armazenamento da formulação e aumento da segurança para o paciente com respeito a possíveis 'erros' durante o manuseio. De fato, o fato de ter semelhantes formulações estáveis em temperatura ambiente reduz o risco de formação de produtos de degradação potencialmente responsáveis por eventos adversos (por exemplo, imunogenicidade).
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP03104646 | 2003-12-11 | ||
EP04103349 | 2004-07-13 | ||
PCT/EP2004/053407 WO2005058346A1 (en) | 2003-12-11 | 2004-12-10 | Stabilized interferon liquid formulations |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0416980A true BRPI0416980A (pt) | 2007-02-21 |
Family
ID=34702349
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0416980-8A BRPI0416980A (pt) | 2003-12-11 | 2004-12-10 | formulações lìquidas de interferon estabilizadas |
Country Status (18)
Country | Link |
---|---|
US (1) | US7846427B2 (pt) |
EP (1) | EP1691825B1 (pt) |
JP (1) | JP4658961B2 (pt) |
AT (1) | ATE526032T1 (pt) |
AU (1) | AU2004298781B2 (pt) |
BR (1) | BRPI0416980A (pt) |
CA (1) | CA2547822A1 (pt) |
CY (1) | CY1112193T1 (pt) |
DK (1) | DK1691825T3 (pt) |
ES (1) | ES2374530T3 (pt) |
HR (1) | HRP20110699T1 (pt) |
IL (1) | IL176021A0 (pt) |
NO (1) | NO20063108L (pt) |
PL (1) | PL1691825T3 (pt) |
PT (1) | PT1691825E (pt) |
RS (1) | RS52218B (pt) |
SI (1) | SI1691825T1 (pt) |
WO (1) | WO2005058346A1 (pt) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI272948B (en) * | 2003-05-01 | 2007-02-11 | Ares Trading Sa | HSA-free stabilized interferon liquid formulations |
KR20070012464A (ko) * | 2004-05-17 | 2007-01-25 | 아레스 트레이딩 에스.아. | 하이드로겔 인터페론 제제 |
NZ580686A (en) | 2007-05-02 | 2012-11-30 | Ambrx Inc | Modified interferon beta polypeptides and their uses |
US7951368B2 (en) | 2007-06-25 | 2011-05-31 | Amgen Inc. | Compositions of specific binding agents to hepatocyte growth factor |
CA2707840A1 (en) | 2007-08-20 | 2009-02-26 | Allozyne, Inc. | Amino acid substituted molecules |
EA201070773A1 (ru) * | 2007-12-20 | 2010-12-30 | Мерк Сероно С. А. | Составы пэг-интерферона-бета |
US20100203014A1 (en) * | 2009-02-04 | 2010-08-12 | Aegis Therapeutics Llc | Zwitterionic buffered acidic peptide and protein formulations |
US20150283252A1 (en) * | 2012-10-26 | 2015-10-08 | Lupin Limited | Stable pharmaceutical composition of peginterferon alpha-2b |
GB201604124D0 (en) * | 2016-03-10 | 2016-04-27 | Ucb Biopharma Sprl | Pharmaceutical formulation |
MX2020007270A (es) * | 2017-09-27 | 2020-08-17 | Novartis Ag | Formulacion parenteral que comprende siponimod. |
CN111494611A (zh) * | 2020-06-08 | 2020-08-07 | 长春生物制品研究所有限责任公司 | 一种卡式瓶多剂量笔式注射组合包装的干扰素注射液 |
CN113797317B (zh) * | 2021-10-26 | 2024-01-09 | 科兴生物制药股份有限公司 | 一种组合物及其制备方法和应用 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5997856A (en) * | 1988-10-05 | 1999-12-07 | Chiron Corporation | Method and compositions for solubilization and stabilization of polypeptides, especially proteins |
US6582728B1 (en) | 1992-07-08 | 2003-06-24 | Inhale Therapeutic Systems, Inc. | Spray drying of macromolecules to produce inhaleable dry powders |
US5814485A (en) * | 1995-06-06 | 1998-09-29 | Chiron Corporation | Production of interferon-β (IFN-β) in E. coli |
ZA9610374B (en) * | 1995-12-11 | 1997-06-23 | Elan Med Tech | Cartridge-based drug delivery device |
JP2001526033A (ja) * | 1997-12-08 | 2001-12-18 | ジェネンテク・インコーポレイテッド | ヒトインターフェロン−イプシロンというi型インターフェロン |
US6887462B2 (en) * | 2001-04-09 | 2005-05-03 | Chiron Corporation | HSA-free formulations of interferon-beta |
WO2003002152A2 (en) * | 2001-06-29 | 2003-01-09 | Maxygen Aps | Stabilized formulations of interferons with sulfoalkyl ether cyclodextrins |
TWI272948B (en) | 2003-05-01 | 2007-02-11 | Ares Trading Sa | HSA-free stabilized interferon liquid formulations |
KR20070012464A (ko) | 2004-05-17 | 2007-01-25 | 아레스 트레이딩 에스.아. | 하이드로겔 인터페론 제제 |
CN1993139B (zh) | 2004-06-01 | 2011-02-16 | 阿雷斯贸易股份有限公司 | 稳定的干扰素液体制剂 |
-
2004
- 2004-12-10 PT PT04820468T patent/PT1691825E/pt unknown
- 2004-12-10 ES ES04820468T patent/ES2374530T3/es active Active
- 2004-12-10 US US10/582,027 patent/US7846427B2/en active Active
- 2004-12-10 PL PL04820468T patent/PL1691825T3/pl unknown
- 2004-12-10 BR BRPI0416980-8A patent/BRPI0416980A/pt not_active IP Right Cessation
- 2004-12-10 EP EP04820468A patent/EP1691825B1/en active Active
- 2004-12-10 DK DK04820468.9T patent/DK1691825T3/da active
- 2004-12-10 JP JP2006543556A patent/JP4658961B2/ja active Active
- 2004-12-10 SI SI200431761T patent/SI1691825T1/sl unknown
- 2004-12-10 AU AU2004298781A patent/AU2004298781B2/en active Active
- 2004-12-10 RS RS20110581A patent/RS52218B/en unknown
- 2004-12-10 CA CA002547822A patent/CA2547822A1/en not_active Withdrawn
- 2004-12-10 AT AT04820468T patent/ATE526032T1/de active
- 2004-12-10 WO PCT/EP2004/053407 patent/WO2005058346A1/en active Application Filing
-
2006
- 2006-05-30 IL IL176021A patent/IL176021A0/en active IP Right Grant
- 2006-07-04 NO NO20063108A patent/NO20063108L/no not_active Application Discontinuation
-
2011
- 2011-09-30 HR HR20110699T patent/HRP20110699T1/hr unknown
- 2011-12-06 CY CY20111101217T patent/CY1112193T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
SI1691825T1 (sl) | 2011-12-30 |
PT1691825E (pt) | 2011-10-12 |
PL1691825T3 (pl) | 2012-02-29 |
DK1691825T3 (da) | 2011-12-05 |
IL176021A0 (en) | 2006-10-05 |
US20070104682A1 (en) | 2007-05-10 |
US7846427B2 (en) | 2010-12-07 |
AU2004298781B2 (en) | 2010-04-01 |
JP4658961B2 (ja) | 2011-03-23 |
HRP20110699T1 (hr) | 2011-10-31 |
RS52218B (en) | 2012-10-31 |
EP1691825A1 (en) | 2006-08-23 |
CA2547822A1 (en) | 2005-06-30 |
AU2004298781A1 (en) | 2005-06-30 |
CY1112193T1 (el) | 2015-12-09 |
NO20063108L (no) | 2006-07-04 |
ATE526032T1 (de) | 2011-10-15 |
JP2007513925A (ja) | 2007-05-31 |
EP1691825B1 (en) | 2011-09-28 |
WO2005058346A1 (en) | 2005-06-30 |
ES2374530T3 (es) | 2012-02-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20063108L (no) | Stabiliserte, flytende interferonformuleringer | |
ES2418833T3 (es) | Formulaciones líquidas de interferón estabilizadas | |
DE502004012418D1 (de) | Formulierung für proteinarzneimittel ohne zusatz von humanem serumalbumin (hsa) | |
NO953278L (no) | Fremgangsmåter for in vivo-levering av biologisk aktive stoffer og sammensetninger som er nyttige for dette | |
KR970706017A (ko) | 안정한 알파 인터페론 수용액 제형(Stable, aqueous alfainterfer on solution for mulations) | |
CY1115233T1 (el) | Υγρα σταθεροποιημενα σκευασματα ιντερφερονης-βητα σε επικαλυμμενους περιεκτες φαρμακευτικης χρησης | |
DE69418468D1 (de) | Viskoelastische zusammensetzungen aus organischen fluorierten verbindungen | |
PL335571A1 (en) | Stabilisation of acid-sensitive benzimidazoles by combining them with amino acids and cyclodextrins | |
CA2304808A1 (en) | Liquid interferon-.beta. formulations | |
NO20054440L (no) | Flytende formuleringer av tumornekrosefaktorbindende proteiner | |
UA94032C2 (ru) | Жидкая стабализированная композиция интерферона без hsa | |
HUP0302311A2 (hu) | Gyógyászati aeroszol-készítmények | |
ATE275974T1 (de) | Zusammensetzungen enthaltend glykolderivate, alkohole und vitamin d | |
ATE359777T1 (de) | Fenofibratsäure enthaltende pharmazeutische zusammensetzung und deren physiologisch verträgliche salze und derivate | |
AR017066A1 (es) | Cristales de glicoproteina, de enlazamiento cruzado con carbohidrato | |
KR101699677B1 (ko) | 고나도트로핀을 위한 제제 | |
CO4830457A1 (es) | Preparados efervescentes | |
JP2008050320A (ja) | インターフェロン−β含有医薬組成物 | |
DE60134883D1 (de) | Interferon- und interleukin-derivate mit langzeitwirkung und diese enthaltende pharmazeutische zusammensetzungen | |
RU2238758C2 (ru) | Водный раствор интерферона-альфа-два человека для инъекций | |
ATE223700T1 (de) | Ramoplaninhaltige neue injizierbare arzneizubereitungen | |
BR0215498A (pt) | Composição farmacêutica compreendendo uma glitazona e um ácido 4-oxobutanóico e o seu uso para o tratamento de diabetes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 9A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2260 DE 29/04/2014. |